Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. INOZYME PHARMA, INC. CONFIDENTIAL...Corporate Sponsored Research Agreement • March 15th, 2022 • Inozyme Pharma, Inc. • Pharmaceutical preparations • Connecticut
This RESEARCH AGREEMENT (this “Agreement”) is entered into as of January 6, 2017 (the “Effective Date”), by and between Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the “University”), and Inozyme Pharma, LLC, a Delaware limited liability company, having its principal offices at 240 Bluff View Drive, Guilford, Connecticut 06347 (the “Sponsor”).
CONSULTING AGREEMENTConsulting Agreement • March 15th, 2022 • Inozyme Pharma, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (the “Agreement”) is entered into and effective as of November 30, 2021 (the “Effective Date”), by and between Inozyme Pharma, Inc., a Delaware corporation having a place of business at 321 Summer Street, Suite 400, Boston, MA 02210 (the “Company”), and Wenkert & Young, LLC, a limited liability company having a place of business at [**] (the “Consultant” and Company and Consultant, each, individually a “Party” and collectively, the “Parties”). In consideration of the mutual covenants set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
VIA ELECTRONIC MAIL November 3, 2021 (as revised on November 30, 2021) Deborah Wenkert, MD Dear Deb:Consulting Agreement • March 15th, 2022 • Inozyme Pharma, Inc. • Pharmaceutical preparations • California
As we have discussed, you are separating from employment with Inozyme Pharma, Inc. (the “Company”) for good reason, effective November 30, 2021 (the “Separation Date”). As we also discussed, you will be eligible to receive the severance benefits described in paragraph 1 below if you materially comply with the terms and conditions of this letter agreement, sign and return this letter agreement to me on, but not before, the Separation Date, and do not revoke your agreement (as described below). By signing and returning this letter agreement and not revoking your acceptance, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 2. Therefore, you are advised to consult with an attorney before signing this letter agreement and you have been given at least twenty-one (21) days to do so. If you sign this letter agreement, you may change y
